With an unprecedented number of new investigational agents and companies in immuno-oncology (IO), it has been difficult to track and understand the current IO agents in clinical development and the clinical trials testing these agents. The Clinical Accelerator team presents an unbiased, neutral, scientifically curated, and timely updated analysis based on information collected from numerous trusted and publicly available sources.
We hope to inform the cancer research community through academic publications as it strives for efficiencies and innovation while avoiding duplication. As of today, we have five landscape publications:
- The global pipeline of cell therapies for cancer, Nature Reviews Drug Discovery, May 2019
- The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors, Nature Reviews Drug Discovery, November 2018
- Trends in the global immuno-oncology landscape, Nature Reviews Drug Discovery, October 2018
- The global landscape of cancer cell therapy, Nature Reviews Drug Discovery, May 2018
- Comprehensive analysis of the clinical immuno-oncology landscape, Annals of Oncology, December 2017
Additionally, data from our Immuno-Oncology Landscape has been featured in a review of IO combination trials in breast cancer:
A global pipeline of cancer cell therapies. 1,011 cancer cell therapies in the current pipeline of 2019, compared to 753 therapies in 2018, are included in the interactive dashboard. The top graph serves as the filter to curate the following two graphs. Seven different classes of cell therapies are defined based on their mechanism of actions. More details and other analyses can be found in the Nature Reviews Drug Discovery article
published on May 30, 2019.
A comparison of global IO pipelines in 2017 and 2018. 3,394 immuno-oncology agents in six main classes were identified in September 2018, an increase of 67% since the previous survey. More details can be found in the Nature Reviews Drug Discovery
Timeline of Anti-PD-1/L1 Antibody Approvals by the FDA
Timeline of non-PD-1/PD-L1 Immuno-Oncology Agent Approvals by the FDA
Data Sources: Cancer Research Institute (CRI) analytics derive from public data sources, including trade news, company press releases, academic publications, FDA announcements, clinicaltrials.gov, and conference reports, and proprietary data sources including, but not limited to, GlobalData. The analytical algorithm and visualizations are developed by and therefore sole property of Cancer Research Institute.
Subscribe to our email newsletter to receive the latest updates on our landscape analyses.